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1. Introduction 
Many kinds of cells contain a large pool of unpolym- 
erised actin and there is evidence for conversion of 
unpolymerised to filamentous actin as a response to 
stimuli resulting in cell movements ([l-4], reviewed 
[5,6]). An unpolymerised form of actin has been puri- 
fied from extracts of various kinds of cells as a 1: 1 
complex with a protein called profilin, which prevents 
the polymerisation of the actin. Profilin, isolated 
from calf spleen, thymus and brain and from human 
platelets can combine with rabbit skeletal muscle 
actin and prevent its polyme~sation ([7,8], Blikstad, 
Sundquist and Eriksson, unpublished results). The 
profhn : actin complex (profilactin) from calf 
spleen has been crystallized [9] and crystals suitable 
for high resolution X-ray crystallography have been 
obtained. The amino acid sequence of actin and 
profilin will be useful in solving the crystal structure 
of profilactin and for the detailed characterisation of 
its biochemical properties. The amino acid sequence 
of actin from various sources has been reported 
[ 10,l l]. This paper describes the amino acid sequence 
of profilin from calf spleen. 
2. Materials and methods 
Profilactin from calf spleen was purified as in [9]. 
Profilin was isolated from protilactin either by the 
‘urea method’ [7] or by dissociation of the complex 
with 5 mM EGTA [ 121. 
Profdin (1 pmol) was carboxymethylated with 
iodo-[r4C]acetic acid by the method in [ 131. Modifi- 
cation of lysine residues with citraconic a~ydride 
was performed using the conditions in [ 141. 
Cleavage of carboxymethylated profilin (1 pmol) 
with cyanogen bromide was carried out at room 
temperature in 70% formic acid [ 151. The peptide 
mixture was fractionated on Sephadex G-25 SF 
(Pharmacia, Sweden) in 25% formic acid. The pep- 
tides of pool II (fig. 1 a) were further purified by 
high-voltage paper electrophoresis at pH 6.5 and 2.1 
according to [ 161 and by chromatography in the 
second dimension using the BAWP solvent system 
[ 171. Fragments of profilin were also generated with 
[‘4C]cyanide using the cyanocysteine cleavage method 
[ 181 and fractionated on Sephadex G-25 SF in 
50 mM NH4HC0a. Two peaks containing the peptides 
Cya 2 and 1, respectively, were eluted. The N-terminal 
region of the Cya 1 peptide was sequenced by mass 
spectrometry. The Cya 2 peptide was further digested 
with chymotrypsin and the peptides obtained were 
sequenced using the Dansyl-Edman method (see 
below). The remaining fragments were retained by 
the column, but could be eluted with 50% acetic acid. 
However, this material was not analyzed further. 
Carboxymethylated freeze dried profilin (1 pmol) 
was dissolved in 8 M urea, 0.4 M Tris-HCI (pH 8.0) 
and diluted to I M urea, 5 mM CaC12 before digestion 
with chymotrypsin. Chymotrypsin (3 X crystallized, 
Worthington) was added to a substrate : enzyme ratio 
(w/w) of 100: 1. The mixture was incubated at 37°C 
with stirring. After 4 h digestion more chymotrypsin 
was added (find substrate : enzyme ratio of 50: 1, 
w/w) and incubation continued over night. The 
insoluble residue left after digestion was removed by 
centrifugation and washed 3 times with 50 mM 
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NH,HCOa. The soluble peptides were fractionated on 
a Sephadex G-25 SF column in 50 mM NH4HC0a 
(fig.1 b) and further purified by high-voltage paper 
electrophoresis and chromatography as outlined 
above. 
Trypsin (Worthington) was further purified by 
affinity chromatography on soybean trypsin inhibitor 
coupled to Sepharose 4B [ 191. Carboxymethylated 
profilin (1 ,umol) was suspended in 2 M urea, 50 mM 
NH4HC0, (PH 8.5) 20 mM CaCl, and incubated 
with trypsin at a substrate : enzyme ratio of 50: 1 
(w/w) for 4 h at 37°C. Soluble tryptic peptides were 
separated and further fractionated by electrophoresis 
and chromatography. 
The large peptide CT was prepared by trgptic 
digestion of citraconylated profilin (1 pmol) using a 
substrate : enzyme ratio of 100: 1 (w/w) at 37°C. 
After 4 h the reaction was stopped and unblocking 
was performed by incubating with 2 vol. 5% formic 
acid/ 1% pyridine at room temperature overnight. The 
digest was fractionated on a Sephadex G-25 column 
(16X 900mm)in lOmMHC1. 
Protease from Staphylococcus aureus strain V8 
(Miles Biochemical Co.) was used for further digestion 
of peptide Ch3 in 50 mM NH,HCOa @H 8.5) for 
4 h at 37°C at a substrate : enzyme molar ratio of 
50: 1. The C-terminal sequence of peptide Ch3 was 
determined using DFP-treated carboxypeptidase A 
(Worthington) as described by Ambler using a 
substrate : enzyme molar ratio of 5O:l [20]. 
The sequences of most peptides were determined 
by the Dansyl-Edman method [21] using thin-layer 
chromatography to identify the dansylated amino 
acid [22]. The amides were assigned by the method 
in [23]. The large peptide CT (fig.2) was sequenced 
Fig.1. Fractionation of peptides from cleavage of profilin 
with cyanogen bromide, chymotrypsin and trypsin on 
Sephadex G-25 SF. (a) The cyanogen bromide peptides were 
separated on a 16 X 900 mm column in 25% formic acid. 
Fraction II contained peptides CNBr 1, 2 and 3 (see fig.2). 
(b) Chymotrypticpeptides were fractionated on 25 X 500 mm 
column in 50 mM NH,HCO,. Fraction I contained peptides 
Ch3, Ch6 and Ch9: fraction II Ch5, Chl 1; fraction III Ch4, 
Ch7, Ch8, Ch12;fraction IV Chl, Ch2, ChlO. (c) Tryptic 
peptides were fractionated on a 25 X 500 mm column in 
50 mM NH,HCO,. Fraction I contained peptides Tl, T9, 
TlO; fraction II T2, T5, T7; fraction III T6, Tll; fraction IV 
T4, T8. 
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on a Beckman model 890-B automatic sequencer 
using the 0.1 M Quadrol program [24]. The PTH 
amino acids from each step were identified by thin- 
layer chromatography [25] gas-liquid chromatog- 
raphy [26], and after back hydrolysis [27] the result- 
ing amino acids were determined on a Durrum D-500 
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amino acid analyzer. The N-terminal region was deter- 
mined for us by Drs Ann Dell and Howard Morris 
(Imperial College, London) using mass spectrometry 
WI. 
3. Results and discussion 
Profdin has mol. wt 15 000-16 000 as determined 
by SDSpolyacrylamide gel electrophoresis and it 
chromatographs as a monomer under non-denaturing 
conditions. It is a basic protein with a p1 between 
pH 9.2 and 9.4. It has 2 tryptophanes and 4 tyrosines 
and its E$ is 13. Profilin has 3 cysteine residues and 
its N-terminus is blocked. The amino acid composi- 
tion of profiins from different sources are similar 
suggesting that protilin is a conserved protein [8]. 
The amino acid sequence of profiin was deter- 
mined in the following way. Cleavage of carboxy- 
methylated profilin with cyanogen bromide gave rise 
to peptides which were fractionated as shown in 
fig.la. Three peptides (CNBr 1,2,3, see fig.2) were 
isolated from fraction II by paper electrophoresis and 
chromatography and sequenced. One of these peptides 
was the homoserine-lacking C terminal peptide. 
Fraction I contained peptides which proved difficult 
to separate and they were not analyzed further. 
Carboxymethylated profdin was digested with 
chymotrypsin in 1 M urea. The addition of urea was 
essential as neither trypsin nor chymotrypsin would 
reproducibly degrade the profilin molecule in its 
absence. However, even after prolonged digestion 
with chymotrypsin, insoluble material remained. This 
material ‘chymo-insoluble’ was collected by centri- 
fugation and analysed as described below. The soluble 
peptides were fractionated as described in section 2 
and fig.lb. Peptides Ch2, Ch4, Ch5, Ch6, Ch7, Ch8, 
ChlO, Chll and Ch12 were sequenced by the manual 
Dansyl-Edman technique. The sequence of Ch9 was 
completed by sequencing the overlapping tryptic 
peptide T7 (see below). Only the first 6 amino acids 
of peptide Ch3 could be sequenced. This peptide was 
later shown to part of the N-terminal tryptic peptide 
Tl . Its sequence and the sequence of the ‘chymo- 
insoluble’ remaining after digestion with chymo- 
trypsin is described below. 
Carboxymethylated profhn was digested with 
trypsin in the presence of 2 M urea. Insoluble material 
left after digestion contained one major peptide, T3. 
The supernatant was fractionated on Sephadex G-25 
SF (fig.lc). The peptides T2, T4, T6, T8, TlO and 
Tl 1 were sequenced. The sequence of T5 was estab- 
lished after comparison with the overlapping peptide 
Ch8. To obtain the sequences of T3 and T7 these 
peptides were further digested with chymotrypsin. 
The peptide Tl could not be sequenced using the 
Dansyl-Edman method. It had an amino acid com- 
position similar to that of the chymotryptic peptide 
Ch3 and on chymotrypsin digestion Tl gave rise to 
Ch3, a peptide Ch2, free lysine and a tryptophane- 
containing peptide (Chl). Sequencing of Tl by mass 
spectrometry gave Acetyl-Ala-Gly-Trp-Asn-Ala. 
This positioned Chl and Ch2. The overlap between 
Ch2 and Ch3 was obtained by the isolation of a 
peptide (res 4-l 0) arising from a partial cleavage of 
profilin with chymotrypsin. The sequence around 
position 20 was ascertained by the analysis of a 
peptide (res 19-23) obtained from peptide Ch3 by 
digestion using staphylococcal protease. Carboxy- 
peptidase digestion gave the C-terminal sequence 
(res 20-24). The overlap between Tl and T2 was 
confirmed by tryptic cleavage of the cyanolation 
fragment Cya 2. 
The ‘chymo-insoluble’ contained all the missing 
threonine residues of the molecule, and the overall 
composition suggested that it included the region 
which remained to be sequenced. It was heterogenous 
and digestion of citraconylated ‘chymo-insoluble’ 
with trypsin yielded small amounts of two peptides 
(res 66-88, res 84-88) together with a large peptide 
which became insoluble after removal of blocking 
groups. The N-terminal of the insoluble peptide 
indicated that it started at residue 89, but further 
sequence data was very difficult to obtain. The 
sequence of this region was obtained as follows. 
Peptides obtained by digesting the citraconylated 
profilin with trypsin were found to be soluble after 
unblocking the lysine residues and they could be 
fractionated on Sephadex G-25 SF in 10 mM HCl 
(data not shown). The material appearing with the 
void volume contained the expected peptide (CT, 
res 89-138) together with small amounts of a 
peptide representing T5 and T6. The solubility 
property of the peptide CT was radically different 
from that of ‘chymo-insoluble’ and its sequence 
from res 89-123 was determined using the spinning 
163 
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cup sequencer. This gave an overlap into the known 
C-terminal sequence. 
Profrlin contains 142 amino acid residues giving it 
mol. wt 15 220. The N-terminal amino acid is 
acetylated. Using the computer program in [29,30], 
the primary structure of profilin was compared with 
the known sequence of proteins related to the 
actomyosin system: actin, light chalrrs from rabbit 
skeletal muscle myosin and molluscan myosin, muscle 
tropomyosin, troponin subunits and pancreatic 
DNase 1. No sequence homologies were found. The 
actin binding region of troponin I has been identified 
[3 I] and contains a high proportion of basic amino 
acids (a net positive charge at pH 7 or 8). The 
C-terminal region of profihn aIs0 contains a high net 
positive charge. This is of interest as the basic region 
of troponin I is suggested 13 t f to interact with f he 
acidic N-terminus of actin. 
A secondary structure of profilin was determined 
using a computer program based on the prediction 
rules in [32], As shown in fig.2 the N-terminizl half 
of the profilm molecule is suggested to contain mainly 
P-sheet structure and the C-terminal half to to con- 
tain o-helical structure. We eagerly await the tertiary 
structure of prafilactin to test these predictions, 
la 20 
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Fig.2 The amino acid sequence of calf spleen prul‘ilin. Abbreviations: chymotryptic peptides, Ch; tryptic peptides, T; cyanogcn 
bromide fragments, CNBr; cyanolation fragments, Cya; and citraconylated tryptic fragment, CT. 
The terminology used in the secondary structure predictions is (0) for a-hek% (=I for b-sheet, (~1 for turn. 
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